News

Researchers at the Second University of Naples and the University of Parma in Italy recently characterized the microstructural brain alterations in patients with amyotrophic lateral sclerosis (ALS) during disease progression. The findings were published in the journal PLoS ONE and the study is entitled…

Pharmaceutical company AB Science SA received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy for amyotrophic lateral sclerosis (ALS), called masitinib. The drug is a protein kinase inhibitor (PKI) and was granted the status in order to accelerate its…

A recent study from Sweden’s KTH Royal Institute of Technology (KTH) revealed three proteins that are associated with the progress of amyotrophic lateral sclerosis (ALS). The research team from the KTH and Science for Life Laboratory led by Anna Häggmark believe that the research is the most comprehensive plasma…

Massachusetts-based pharmaceutical company Biogen Idec Inc. has decided to rebrand the company with a shorter name and a new logo, as well as by refocusing its work and abandoning its near exclusivity to multiple sclerosis (MS) drugs to also include research on conditions such as amyotrophic lateral sclerosis (ALS).

A research team at Penn Medicine recently found that hypermethylation is able to inhibit the development of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) in a study titled, “C9orf72 promoter hypermethylation is neuroprotective: Neuroimaging and neuropathologic evidence.” The results are published in the journal…

Researchers at Johns Hopkins University recently published in the journal PLOS ONE a novel resource to aid in studies focused on amyotrophic lateral sclerosis (ALS) pathogenesis and related drug development. The study is entitled “A Comprehensive Library of Familial Human Amyotrophic Lateral Sclerosis…

Results from a recent Phase I clinical trial in patients with Amyotrophic Lateral Sclerosis (ALS) showed a safe cell therapy approach that may allow for the treatment of larger pools of patients for later-phase ALS trials. The study is published in the Journal of Translational Medicine.

The ALS Association is inaugurating its new Nevada Chapter after the group joined 39 affiliates throughout the country to work in collaboration with the local community in order to support finding effective treatments and a cure for amyotrophic lateral sclerosis (ALS). The National Board of Trustees of the association recently praised…

In a new study entitled “Exome sequencing of case-unaffected-parents trios reveals recessive and de novo genetic variants in sporadic ALS,” researchers report to have identified rare genetic variants underlying sporadic cases of amyotrophic lateral sclerosis. The study was published in the journal Scientific…

A new study on amyotrophic lateral sclerosis (ALS) provided evidence that certain areas of gray matter (GM) are disproportionately and asymmetrically vulnerable to the pathology of ALS. The study entitled “Exposing asymmetric gray matter vulnerability in amyotrophic lateral sclerosis” was published on the…